Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
168.52
+4.34 (2.64%)
At close: Jun 26, 2026, 4:00 PM EDT
167.83
-0.69 (-0.41%)
After-hours: Jun 26, 2026, 7:49 PM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 29 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $194.38. The average 1-year stock price forecast is 15.35% higher than the current stock price, while the lowest is $144 (-14.55%) and the highest is $250.65 (+48.74%).
Price Target: $194.38 (+15.35%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 19 | 20 | 20 | 19 | 20 | 21 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 4 | 4 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 27 | 28 | 28 | 27 | 28 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Buy Maintains $181 | Buy | Maintains | $181 | +7.41% | Jun 16, 2026 |
| Citi | Citi | Buy Maintains $246 | Buy | Maintains | $246 | +45.98% | Jun 16, 2026 |
| William Blair | William Blair | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 2, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $213 | Buy | Initiates | $213 | +26.39% | Jun 2, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $180 → $183 | Buy | Maintains | $180 → $183 | +8.59% | May 29, 2026 |
Financial Forecast
Revenue This Year
3.77B
from 2.86B
Increased by 31.95%
Revenue Next Year
4.49B
from 3.77B
Increased by 18.96%
EPS This Year
10.39
from 6.39
Increased by 62.67%
EPS Next Year
12.68
from 10.39
Increased by 21.94%
EPS and Forward PE are based on non-GAAP adjusted numbers.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.0B | ||
| Avg | 3.8B | ||
| Low | 3.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 38.9% | ||
| Avg | 32.0% | ||
| Low | 19.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 17.37 | ||
| Avg | 10.39 | ||
| Low | 8.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 171.8% | ||
| Avg | 62.7% | ||
| Low | 29.4% |